Obatoclax (803712-79-0) is a novel Bcl-2 homology domain-3 (BH3) mimetic.1 Inhibits primary acute myeloid leukemia (AML) progenitor cell proliferation (IC50=0.18 μM) and induces apoptosis in primary AML cells (IC50= 3.6 μM).2 Obatoclax synergizes with other agents such as chloroquine3 and cytarabine4(cat.# 10-1268) in cytotoxicity against a variety of cancer cells.
1) Chonghaile and Letai (2008), Mimicking the BH3 domain to kill cancer cells; Oncogene, 27 S149
2) Konopleva et al. (2008), Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax); Cancer Res., 68 3413
3) Wang et al. (2014), Combination of chloroquine and GX15-070 (obatoclax) results in synergistic cytotoxicity against pancreatic cancer cells; Oncol. Rep., 32 2789
4) Xie et al. (2015), Obatoclax potentiates the cytotoxic effect of cytarabine on acute myeloid leukemia cells by enhancing DNA damage; Mol. Oncol., 9 409